Premium
HLA ‐ DRB 1*04:05 in two cases of Vogt–Koyanagi–Harada disease‐like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy
Author(s) -
Fujimura Taku,
Kambayashi Yumi,
Tanita Kayo,
Sato Yota,
Hidaka Takanori,
Otsuka Astushi,
Tanaka Hidenori,
Furudate Sadanori,
Hashimoto Akira,
Aiba Setsuya
Publication year - 2018
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.14273
Subject(s) - dabrafenib , medicine , nivolumab , uveitis , trametinib , melanoma , dermatology , disease , adverse effect , immunology , immunotherapy , metastatic melanoma , vemurafenib , cancer research , immune system , mapk/erk pathway , kinase , biology , microbiology and biotechnology
Although uveitis is reported as a rare adverse event ( AE ) associated with dabrafenib/trametinib therapy or nivolumab, the occurrence of severe uveitis is extremely rare. We describe two cases of Vogt–Koyanagi–Harada ( VKH )‐like uveitis developing after the sequential administration of nivolumab and dabrafenib/trametinib therapy. Interestingly, both cases had HLA ‐ DRB 1*04:05, which is strongly associated with VKH disease, and achieved biologically complete remission after the treatment for uveitis. Our cases suggest a possible correlation between VKH ‐like uveitis as an AE and the clinical outcomes of sequential administration of nivolumab and dabrafenib/trametinib therapy for the treatment of advanced melanoma.